CorMedix Inc

CorMedix Inc(CRMD)價格預測

$8.380

+0.122 (+1.45%)收盤時

價格預測

1-Day Price Prediction
+0.59%
1-Week Prediction
+0.41%
1-Month Prediction
2026 Prediction
2030 Prediction

在 App 中開啟以解鎖更長週期的預測。

Loading chart…

CRMD 相似圖表分析預測

Alphio's CRMD stock price prediction model matches the current CorMedix Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $8.43 (+0.59%). The 1-week path is $8.41 (+0.41%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

該買進 CorMedix Inc 股票嗎?

CorMedix Inc (CRMD) is a good buy right now due to its recent strong financial performance, including a Q2 revenue of $101.9 million, which is a significant increase from $39.7 million a year ago, and a gross margin of 75.66%. Additionally, analysts have set a price target of $14, suggesting a 59.27% upside from the current price of $8.3. The main risk is the year-to-date change of -31.74%, indicating volatility in the stock's performance.

CRMD 股價於 Tuesday 收在 $8.38,此前上漲 +1.45%

CorMedix Inc (CRMD) last closed at $8.38, gaining +1.45%. These facts feed the 1-day and 1-week CRMD price prediction above.

分析師一致預期

CorMedix Inc(CRMD):買進 1、持有 0、賣出 0。展望:Strong Buy。

Technical signals summary based on buy and sell indicators. The gauge shows the overall market view.

Strong sellSellNeutralBuyStrong buy
Neutral
Sell
0
Buy
1

預測驅動因素

CorMedix Inc(CRMD)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。

Similar patterns

Positive

Bullish

Seasonality

Positive

Bullish

SMA 20

Positive

Bullish

SMA 200

Positive

Bullish

相似圖表形態

近期走勢與 CRMD 最接近的股票,依相似度排序。

CRMD 季節性分析

Historically the probability of a positive September return for CRMD is 97.62%. October offers the highest probability of a positive month at 100.00%, while January is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.

Loading chart…

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始